Kirkland's And 2 Other Stocks Under $3 Insiders Are Buying

The Dow Jones closed lower by around 10 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Kirkland's

• The Trade: Kirkland's, Inc. KIRK President, COO Amy E. Sullivan acquired a total of 2,847 shares an average price of $1.76. To acquire these shares, it cost around $4,999.
• What’s Happening: Kirkland's reported weaker-than-expected second-quarter FY23 results.
• What Kirkland's Does: Kirkland's Inc is a specialty retailer of home decor and gifts in the United States.

Vivani Medical

• The Trade: Vivani Medical, Inc. VANI Director Gregg Williams acquired a total of 9,924 shares at an average price of $1.00. To acquire these shares, it cost around $9,924.
• What’s Happening: Vivani Medical recently posted a wider-than-expected second-quarter loss.
• What Vivani Medical Does: Vivani Medical Inc is a preclinical stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases.

Check This Out: Check Out 3 High-Yielding Dividend Stocks In Tech And Telecom Sector From Wall Street's Most Accurate Analysts

Lixte Biotechnology Holdings

• The Trade: Lixte Biotechnology Holdings, Inc. LIXT President and CEO Bastiaan van der Baan acquired a total of 10,000 shares at an average price of $2.80. The insider spent $28,000 to buy those shares.
• What’s Happening: The company’s stock fell around 73% over the past six months.
• What Lixte Biotechnology Does: Lixte Biotechnology Holdings Inc is a drug discovery company that has a developed unique, proprietary, first-in-class protein phosphatase inhibitor, LB-100, as its lead clinical compound.

Don’t forget to check out our premarket coverage here